1 × 10-5 vs 3.7 × 10-4 ± 6.0 × 10-5, p = 0.079). Crossbars indicate median values. Figure 3 Hepatic MRP2 expression level of jaundice and jaundice-free group in BA patients. MRP2 expression level did not differ significantly between the jaundice and jaundice-free groups (2.0 × 10-4 ± 2.9 × 10-5 vs 3.1 × 10-4 ± 6.2 × 10-5, p = 0.094). Crossbars indicate median values. Next, the

association between see more MRP2 expression and the serum level of total bilirubin in the perioperative period was assessed. The serum level of total bilirubin just before surgery did not correlate with MRP2 expression level (rs = 0.031, p = 0.914). The serum level of direct bilirubin just before surgery also had no correlation (rs = -0.016, p = 0.956). The serum level of total bilirubin measured at 2 weeks (rs = -0.569, p = 0.034) and 4 weeks after surgery (rs = -0.620, p = 0.018) correlated with MRP2 expression Saracatinib in vitro levels (Figure 4). The serum level of direct bilirubin

measured at 4 weeks after surgery (rs = -0.577, p = 0.031) also correlated with MRP2 expression levels, but that measured at 2 weeks after the surgery did not (rs = -0.477, p = 0.085). Furthermore, MRP2 expression levels were also inversely correlated with ratio of change in the serum level of total bilirubin during the 4 weeks after surgery (rs = -0.676, p = 0.008), which represent the serum level of bilirubin measured at 4 weeks after surgery divided by value just before surgery. The ratio of change in the serum level of direct bilirubin during 2 weeks (rs = -0.543, p = 0.045) and 4 weeks (rs = -0.586, p = 0.028) also correlated with MRP2 expression Fossariinae levels, although BLZ945 values of total bilirubin during 2 weeks did not. Figure 4 Association between hepatic MRP2 expression level and level of total bilirubin at 4 weeks after surgery. MRP2 expression levels correlated with serum levels of total bilirubin measured at 4 weeks after surgery

(rs = -0.620, p = 0.018). The data in Figure 5 shows MRP2 expression level of BA at primary hepatoportoenterostomy and at a secondary surgical procedure, respectively. Although statistical analysis could not be applied because of the small number of patients, in all 3 cases that underwent 2 surgical procedures, MRP2 expression level at the secondary procedure increased compared with levels at the first hepatoportoenterostomy. Figure 5 Hepatic MRP2 expression level of BA patients at the time of hepatoportoenterostomy and secondary surgical procedure. Squares indicate patients who underwent both hepatoportoenterostomy and a secondary surgical procedure. In these 3 cases, MRP2 expression level at the secondary surgical procedure increased compared with levels seen at the initial hepatoportoenterostomy. There was no correlation between expression level of MRP2 and any nuclear receptor: RXRα (rs = -0.164, p > 0.05), FXR (rs = 0.373, p > 0.05), PXR (rs = 0.409, p > 0.05) and CAR (rs = 0.0257, p = 0.940).